Notably, epigenetic modifiers frequently showed more mutations in AYAs, including H3F3A, KDM5A and IDH1/2 in glioma, EP300 in liver cancer, SMARCA4 in ovarian cancer, and MEN1 in pancreatic cancer. This evidence concerns the gene EP300 and familial pancreatic carcinoma.